Treatment Outcomes of Oropharyngeal Cancer Patients Treated with Radiotherapy in Maharaj Nakhon Si Thammarat Hospital
Keywords:
Oropharyngeal cancer, Radiotherapy, 2-year overall survival, Median Progression free survivalAbstract
Background: Oropharyngeal cancer (OPC) is the type of head and neck cancer (HNCs) consisting of cancer of the base of the tongue, the tonsils, soft palate, and posterior and lateral pharyngeal walls. The incidence of OPC is increasing globally, and radiotherapy remains as treatment cornerstone. Nevertheless, there is limited data regarding the efficacy of OPC treatment in Thailand.
Objective: To evaluate survival outcomes for patients with oropharyngeal carcinoma who were treated with radiation in Maharaj Nakhon Si Thammarat Hospital.
Material and Methods: The retrospective study was conducted, including patients with newly diagnosed oropharyngeal cancer treated with radiotherapy. The primary endpoint was the 2-year overall survival rate. Secondary endpoints were overall survival (OS) and median progression free survival (PFS), estimated by the Cox’s proportional hazard model.
Results: From January 2020 to December 2022, 67 patients with oropharyngeal cancer received radiotherapy. Sixty-five patients (97%) had squamous cell carcinoma; 95 % were male with a median age of 61. Stage IV disease were accounted for 58%, with 52 patients (78%) were treated with concurrent chemoradiation (CCRT). The 2-year OS was 48 %. The median OS and PFS were 23.8 and 19.8 months. After treatment completion, 68% of patients had no tumor recurrence.
Conclusion: The survival outcome of patients with oropharyngeal cancer in Maharaj Nakhon Si Thammarat was comparable to other studies. Longer follow-up periods are needed to assess delayed benefit to radiotherapy.
References
Smith CDL, McMahon AD, Purkayastha M, Creaney G, Clements K, Inman GJ, et al.Head and neck cancer incidence is rising but the sociodemographic profile is unchanging: a population epidemiological study (2001–2020).BJC reports 2024;2:71-7.
National cancer institute department of medical services ministry of public health Thailand Hospital-Based Cancer Registry 2022;38:1-2.
Rojanamatin J, Ukranun W, Supaattagorn P,Chiawiriyabunya I,Wongsena M, Laowahutanont P,et al.Cancer in Thailand Vol.X,2016-2018;2021:10:15-7.
Galbiatti AL, Padovani-Junior JA, Maniglia JV, Rodrigues CD, Pavario EC, Goloni-Bertollo EM. Head and neck cancer: cause, prevention and treatment. Brazilian Journal of Otorhinolaryngology 2013;79:239-47.
Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res 2008;87:14-32.
Bisht M, Bist SS. Human papilloma virus: a new risk factor in a subset of head and neck cancers. J Cancer Res Ther 2011;7:251-5.
D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Eng J Med 2007;356:1944-56.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Head and Neck Cancer Version 1.2025-November 26,2024.
Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI,et al. Randomized Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas in the Radiation Therapy Oncology Group 0129 Trial: Long-Term Report of Efficacy and Toxicity. J Clin Oncol 2014;32:3858–66.
Bird T, De Felice F, Michaelidou A, Thavaraj S, Jeannon J.–P, Lyons A, et al. Outcomes of intensity-modulated radiotherapy as primary treatment for oropharyngeal squamous cell carcinoma – a European single institution analysis. Clin Otolaryngol 2017;42:115-22.
Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76.
Cvek J, Knybel L, Skacelikova E, Stransky J, Matousek P, Zelenik K, et al. Hyperfractionated stereotactic reirradiation for recurrent head and neck cancer. Strahlenther Onkol 2016;192:40–6.
Marcu LG. Altered fractionation in radiotherapy: From radiobiological rationale to therapeutic gain. Cancer Treat Rev 2010;36:606-14.
Christiansen RL,Gornitzka J,Andersen P,Nielsen M,Johnsen L,Bertelsen AS,et al. Awareness and surveillance of radiation treatment schedules reduces head and neck overall treatment time.Technical Innovations & Patient Support in Radiation Oncology 2019;9:26-30.
Lau F, Lisatchok M, Tamanini JB, Gazmenga FP, Texeira DNA, Couto EV, et al. Treatment outcome of oropharyngeal squamous cell carcinoma through propensity score analysis. Brazilian Journal of Otorhinolaryngology 2023;89:1-6
Kim JC, Park IK. Radiation Therapy for Carcinoma of the Oropharynx. J Korean Soc Ther Radiol 1996;14:95-104.
Semrau R, Temming S, Duerbaum H,Huebbers C, Klussmann JP, Mueller RP, et al. Prognostic Importance of HPV Association in Locally Advanced Inoperable Oropharyngeal Cancer.International journal of Radiation Oncology 2012;84:476.
Sharma A, Kumar M,Bhasker S,Thakar A,Pramanik R,Biswas A.An open-label, noninferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial) Ann Oncol 2019;30:473-4.
De Felice F, Humbert-Vidan L, Lei M, King A, Guerrero Urbano T. Analyzing oropharyngeal cancer survival outcomes: a decision tree approach.Br J Radiol 2020;93:2-7.
Ang KK,Haris J,Wheeler R,Weber R,Rosenthal DI,Nguyen-Tan PF,et al.Human papillomavirus and survival of patients with oropharyngeal cancer.N Engl J Med 2010;363:24–35.
Lechner M,Liu J,Masterson L,Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management .Nat Rev Clin Oncol 2022;19:306-27.
Fakhry C,Zhang Q,Gillison ML,Nguyen-Tân PF,Rosenthal DI,Weber RS,et al Validation of NRG Oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer (OPC); implications for risk-based therapeutic intensity trials. Cancer 2019;125:2027–38.
Yom SS,Torres-Saavedra P,Caudell JJ,Waldron JN,Gillison ML,Xia P,et al.Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).J Clin Oncol 2021;39:956-65.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
เนื้อหาและข้อมูลในบทความที่ลงตีพิมพ์ในมหาราชนครศรีธรรมราชเวชสาร ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรงซึ่งกองบรรณาธิการวารสาร ไม่จำเป็นต้องเห็นด้วย หรือร่วมรับผิดชอบใด ๆ
บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ในมหาราชนครศรีธรรมราชเวชสาร ถือเป็นลิขสิทธิ์ของมหาราชนครศรีธรรมราชเวชสาร หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใด จะต้องได้รับอนุญาตเป็นลายลักษณ์อักษรจากวารสารมหาราชนครศรีธรรมราชเวชสาร ก่อนเท่านั้น
